拉米夫定、α-2b干扰素治疗HBeAg（+）慢性乙型肝炎疗效与基因型相关性研究

李俊; 陈新月; 赵鸿; 于岩岩; 斯崇文; 韩忠厚; 张文谨; 陈宇萍; 陈勇; 王贵强; 于敏; 公维波; 徐京杭; 王军; 蔺小红; 李雪迎

拉米夫定、α-2b干扰素治疗HBeAg（+）慢性乙型肝炎疗效与基因型相关性研究

1. 北京大学第一医院感染疾病科
2. 北京市佑安医院
3. 秦皇岛市第三人民医院
4. 中国人民解放军302医院
5. 保定市传染病医院
6. 淮安市第四人民医院
7. 北京大学第一医院医学统计室

基金项目:

北京市科委病毒性肝炎重大项目(H020920020690)；北京大学211工程循证医学课题(91000-246156054)；

详细信息

中图分类号: R512.6
计量
- 文章访问数: 202
- HTML全文浏览量: 23
- PDF下载量: 151
- 被引次数: 0
出版历程
- 出版日期: 2008-03-20

The relationship of hepatitis B virus genotypes and efficacy of lamivudine and interferon alpha 2b in the treatment of HBeAg-positive chronic hepatitis B

Research funding:

摘要

摘要: 目的探索乙型肝炎病毒（HBV）基因型与拉米夫定、α-2b干扰素序贯治疗及单独予拉米夫定、α-2b干扰素治疗HBeAg阳性慢性乙型肝炎患者的疗效的相关性。方法HBeAg阳性慢乙肝患者,来自北京等四城市。分别拉米夫定、干扰素序贯治疗48周、拉米夫定48周或干扰素24周。停药后随访24周。评价HBV基因型与抗病毒治疗应答的关系。PCR-RFLP方法检测HBV基因型、基因亚型。结果225例患者中C基因型184例,其中C2亚型165例;B基因型41例,均为Ba亚型。治疗结束、随访结束时,各治疗组B型与C型间病毒学应答、血清学应答及完全应答率差异均无显著性。结论该四城市HBeAg阳性慢乙肝患者HBV基因型以B型和C型为主,亚型以Ba和C2亚型为主。治疗结束、随访结束时,各治疗组B型与C型间疗效无差异。
- 拉米夫定 /
- α-2b干扰素 /
- 乙型肝炎病毒 /
- 基因型
Abstract: Objective To study the relationship of hepatitis B virus (HBV) genotypes and the response to antiviral therapy of HBeAg-positive chronic hepatitis B (CHB) patients.Methods 225 CHB patients from four cities were treated by three ways, sequential therapy with lamivudine and interferon α-2b (IFN) for 48 weeks, lamivudine monotherapy for 48 weeks or IFN for 24 weeks.The relationship between HBV genotypes and antiviral responses was investigated.PCR-RFLP was used to typing HBV genotypes and subgenotypes.Results All patients had single genotype, B or C.Every patient with genotype B belonged to subgroup Ba.Genotype C2 was the predominant subgroup in genotype C.There was no significant difference between genotype B and C in antiviral responses in each group at the end of therapy and follow-up.Conclusion Genotypes B and C, subgroups Ba and C2 were predominant in HBeAg-positive CHB patients in these four cities.The antiviral efficacy between genotype B and C in each group had no difference.
- lamivudine /
- interferon alpha 2b /
- HBV /
- genotypes

HTML全文

参考文献(12)

[1]Okamoto H, Tsuda F, Sakugawa H, et al.Typing hepatitis B virusby homology in nucleotide sequence:comparison of surface antigensubtypes[J].J Gen Virol, 1988, 69 (Pt10) ∶2575-2583.

[2]Norder H, Courouce AM, Magnius LO.Complete genomes, phyloge-netic relatedness, and structural proteins of six strains of the hepatitisB virus, four of which represent two new genotypes[J].Virology, 1994, 198 (2) ∶489-503.

[3]Stuyver L, De Gendt S, Van Geyt C, et al.Anewgenotype of hepa-titis B virus:complete genome and phylogenetic relatedness[J].JGen Virol, 2000, 81 (Pt 1) ∶67-74.

[4]Sugauchi F, Kumada H, Sakugawa H, et al.Two subtypes of geno-type B (Ba and Bj) of hepatitis B virus in Japan[J].Clin Infect Dis, 2004, 38 (9) ∶1222-1228.

[5]Mizokami M, Nakano T, Orito E, et al.Hepatitis B virus genotypeassigment using restriction fragment length polymorphismpatterns[J].FEBS Letters, 1999, 450∶66-71.

[6]Tanaka Y, Orito E, Yuen MF, et al, Two subtypes (subgenotypes) ofhepatitis B virus genotype C:A novel subtyping assay based on re-striction fragment length polymorphism[J].Hepatol.Res, 2005, 33 (3) ∶216-224.

[7]范金水, 庄辉, 李远贵, 等.我国8城市HBsAg阳性和阴性乙型肝炎患者病毒血清型和基因型分析[J].中华微生物和免疫学杂志, 1998, 18 (1) ∶88-91.

[8]Kao JH, Wu NH, Chen PJ, et al.Hepatitis B genotypes and the re-sponse to interferon therpy[J].J Hepatol, 2000, 33 (6) ∶998-1002.

[9]Wai CT, Chu CJ, Hussain M, et al.HBV genotype B is associatedwith better response to interferon therpy in HBeAg (+) chronic hep-atitis than genotype C[J].Hepatology, 2002, 36 (6) ∶1425-1430.

[10]Suzuki F, Tsubota A, Arase Y, et al.Efficacy of lamivudine therapyand factors associated with emergence of resistance in chronic hepatitisB virus infection in Japan[J].Intervirology, 2003, 46 (3) ∶182-189.

[11]Yuen MF, Tanaka Y, Lai CL.Hepatitis B gentypes in chronic hep-atitis B and lamivudine therapy[J].Intervirology, 2003, 46 (6) ∶373-376.

[12]Westland C, Delaney WT, Yang H, et al.Hepatitis B virus geno-types and virologic response in 694 patients in phaseⅢstudies ofadefovir dipivoxil[J].Gastroenterology, 2003, 125 (1) ∶107-116.

施引文献

资源附件(0)

访问统计